secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2023-04-18T23:59:59+00:00
Accession:  0000950170-23-013169
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences reports ~$158M cash; DMD gene editing abstract accepted at ASGCT
--------------------------------------------------------------------------------

- Expects ~$158M cash as of March 31, 2023; cash runway through Q1 2025.
- PBGENE-DMD preclinical data selected for oral presentation at ASGCT May 2023.
- ARCUS nucleases designed to excise ~500k bp mutation hot spot in dystrophin gene.
- Abstract available May 2, 2023 on ASGCT website.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017023013169/0000950170-23-013169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017023013169/dtil-20230418.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-013169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer